Ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum evaluated using 3D fluid-attenuated inversion recovery

Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use,...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Fumine, Kogue, Ryota, Maeda, Masayuki, Umino, Maki, Nakai, Yasuo, Takeshita, Atsuro, Sakuma, Hajime
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Neuroradiology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5826684/
https://www.ncbi.nlm.nih.gov/pubmed/29487665
http://dx.doi.org/10.1016/j.radcr.2017.11.007
Descripción
Sumario:Ipilimumab, a human monoclonal antibody against cytotoxic T-lymphocyte antigen 4, was approved by the U.S. FDA (Food and Drug Administration) in 2011 for the treatment of unresectable or metastatic malignant melanoma. Occurrence of hypophysitis, an immune-related adverse event due to ipilimumab use, has been frequently reported. We report a case of ipilimumab-induced hypophysitis involving the optic tracts and tuber cinereum, identified using 3D fluid-attenuated inversion recovery.

Ejemplares similares